Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Arcellx, Inc. - Common Stock
(NQ:
ACLX
)
69.56
+1.11 (+1.62%)
Streaming Delayed Price
Updated: 4:00 PM EST, Dec 5, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Arcellx, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Pharma’s Frontline: 3 Stocks Driving Revolutionary Drug Development
↗
December 15, 2023
These pharma stock leaders offer revolutionary treatments that could change the world of medicine (and investor's portfolios) for the better.
Via
InvestorPlace
Why Johnson Controls International Shares Are Trading Lower By Over 6%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
December 12, 2023
Shares of Johnson Controls International plc (NYSE: JCI) moved lower during Tuesday’s session following weak quarterly results.
Via
Benzinga
Blood Cancer Player Arcellx's Lead Product Exceeds Expectations, Analysts Say
↗
December 11, 2023
Friday, Arcellx Inc (NASDAQ: ACLX) announced new data from its Phase 1 expansion study of CART-ddBCMA, now known as anitocabtagene autoleucel (anito-cel) for relapsed and/or
Via
Benzinga
Where Arcellx Stands With Analysts
↗
December 11, 2023
Via
Benzinga
Analyst Ratings for Arcellx
↗
June 20, 2023
Via
Benzinga
Why Arcellx (ACLX) Stock Is Nosediving
↗
June 20, 2023
Arcellx Inc (NASDAQ: ACLX) shares are trading lower by 8.50% to $32.76 Tuesday morning after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.
Via
Benzinga
The Latest Analyst Ratings for Arcellx
↗
May 18, 2023
Via
Benzinga
Chart Of The Day: Arcellx - Reimagining Cell Therapy
↗
December 08, 2023
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases.
Via
Talk Markets
3 Biotech Stocks That Could Be Multibaggers in the Making
↗
November 30, 2023
Uncover investment opportunities with biotech stocks representing firms developing critical breakthroughs in treatments.
Via
InvestorPlace
Arcellx, A Top 2% Stock, Breaks Out After Inking A $285 Million Deal With Gilead
↗
November 15, 2023
The companies will work together on treatments for multiple myeloma and lymphomas.
Via
Investor's Business Daily
Kite and Arcellx Announce Expansion in Strategic Partnership
November 15, 2023
From
Gilead Sciences, Inc.
Via
Business Wire
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
↗
November 02, 2023
Arcellx Inc (NASDAQ: ACLX) announced that new clinical data from its Phase 1 study of CART-ddBCMA in patients with relapsed or refra
Via
Benzinga
Where Arcellx Stands With Analysts
↗
April 24, 2023
Via
Benzinga
What 5 Analyst Ratings Have To Say About Arcellx
↗
March 30, 2023
Via
Benzinga
Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
↗
November 02, 2023
Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via
Benzinga
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
↗
November 02, 2023
U.S. stocks traded higher, with the Dow Jones gaining more than 350 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Topics
Stocks
7 Biotech Stocks to Get In Now Before Investors Catch On
↗
October 23, 2023
Biotech stocks are down, but there are hidden gems among the rubble. Get in now before the broader market finds them.
Via
InvestorPlace
Cancer Drug Approval? 3 Biotech Stocks on the Brink of Breakthroughs
↗
October 02, 2023
CAR T therapies have major advantages over traditional cancer drugs. Here are three of the best cancer drug stocks set to benefit from CAR T.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
↗
October 17, 2023
Via
Benzinga
Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
↗
August 15, 2023
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 Clinical Program.
Via
Benzinga
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
↗
August 15, 2023
The FDA lifted the partial clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2
Via
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session
↗
August 14, 2023
Via
Benzinga
Arcellx, A Top 5% Biotech, Dives After A 'Perfect Storm' Leads To A Patient's Death
↗
June 20, 2023
A patient died in Arcellx's multiple myeloma drug study. But the underlying factors are complex.
Via
Investor's Business Daily
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
↗
June 20, 2023
The FDA has put a clinical hold on Arcellx Inc's (NASDAQ: ACLX) iMMagine-1 Phase 2 clinical program for CART-ddBCMA investigational new drug for
Via
Benzinga
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
↗
June 20, 2023
Gainers Airspan Networks Holdings Inc. (NYSE: MIMO) shares gained 79.5% to $0.2740.
Via
Benzinga
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
↗
June 20, 2023
Gainers
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
↗
June 20, 2023
It's time for another dive into the biggest pre-market stock movers as we check out all the latest news for Tuesday morning!
Via
InvestorPlace
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
June 20, 2023
U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
↗
May 18, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2023
↗
April 14, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.